Volume 77, Issue 3 pp. 392-395
Human Cancer

Second cancers following in situ carcinoma of the breast

Silvia Franceschi

Silvia Franceschi

Servizio di Epidemiologia, Centro di Riferimento Oncologico, Aviano (PN), Italy

Search for more papers by this author
Fabio Levi

Corresponding Author

Fabio Levi

Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland

Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Centre Hospitalier Universitaire Vaudois, Falaises 1, Casier 15, CH-1011 Lausanne, Switzerland. Fax: (41) 21-323-0303Search for more papers by this author
Carlo La Vecchia

Carlo La Vecchia

Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, and Istituto di Statistica Medica e Biometria, Università Degli Studi di Milano, Milan, Italy

Search for more papers by this author
Lalao Randimbison

Lalao Randimbison

Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland

Search for more papers by this author
Van-Cong Te

Van-Cong Te

Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland

Search for more papers by this author

Abstract

Carcinoma in situ (CIS) of the breast has increased manyfold in incidence rates and as a proportion of new breast cancers following the introduction of mammographic breast screening. To provide population-based estimates of invasive breast cancer risk following CIS, we linked data on 249 incident primary CIS (median age 53 years) to the Cancer Registry of the Swiss Canton of Vaud (about 600,000 inhabitants) over the period 1977–1994. Women with concurrent invasive cancers of the breast were not included. Standardized incidence ratios (SIR) were determined according to the exact Poisson distribution, with stratification for age and year of diagnosis. A total of 24 cases of breast cancer vs. 3.4 expected [SIR = 7.2, 95% confidence interval (CI): 4.6–10.6], and 7 cases of other neoplasms (except non-melanomatous skin cancer) vs. 6.9 expected (SIR = 1.0, 95% CI: 0.4–2.1) were observed. The SIR was 10.4 during the first year, 5.6 between 1 and 4 years, and 7.7 after ≥5 years after CIS diagnosis. SIRs were consistent in women below and above age 55 years, but somewhat higher for ductal (SIR = 8.6) than lobular (SIR = 4.2) CIS. Six deaths from breast cancer were observed vs. 1.5 expected (standardized mortality ratio = 4.0, 95% CI: 1.5–8.7). In 13/19 ductal CIS, but in 2/4 lobular CIS, invasive cancer occurred in the same breast. In most women, CIS and subsequent invasive cancer showed the same morphological (i.e., ductal or lobular) features. The cumulative risk of breast cancer was 16% 10 years after CIS diagnosis, emphasizing the importance of adequate surveillance of women after CIS of the breast. Int. J. Cancer 77:392–395, 1998. © 1998 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.